NULIBRY

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Israel, Lithuania.

Active ingredients

The drug NULIBRY contains one active pharmaceutical ingredient (API):

1	Fosdenopterin UNII X41B5W735T - FOSDENOPTERIN HYDROBROMIDE
	Patients with MoCD Type A have mutations in the Molybdenum Cofactor Synthesis 1 (MOCS1) gene leading to deficient MOCS1A/B dependent synthesis of the intermediate substrate, cPMP. Substrate replacement therapy with fosdenopterin provides an exogenous source of cPMP, which is converted to molybdopterin. Molybdopterin is then converted to molybdenum cofactor, which is needed for the activation of molybdenum-dependent enzymes, including sulphite oxidase (SOX), an enzyme that reduces levels of neurotoxic sulphites.
	Read more about Fosdenopterin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NULIBRY Powder for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AX19		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products
Discover more medicines within A16AX19

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
IL	מִשְׂרַד הַבְּרִיאוּת	9023
LT	Valstybinė vaistų kontrolės tarnyba	1095599
US	FDA, National Drug Code	73129-001